Weekly Spotlight - 09.01.25

Discover New Horizons for Myasthenia Gravis Treatment Solutions

The MAA webinar on 15 January 2025 explores new treatments for Myasthenia Gravis. By attending, you'll learn from neurologists and advocates, discovering how to make impactful submissions to PBAC. Register to access the recording and support better treatment options. Join for knowledge and community empowerment.

PAN Foundation Offers Myasthenia Gravis Premium Assistance for U.S. Patients

The PAN Foundation has launched a programme to help myasthenia gravis patients with health insurance costs. Eligible US patients can receive up to $2,600. This support is vital given myasthenia gravis's chronic nature and high treatment costs. PAN's continuing efforts bring hope through financial and broader community support.

Efgartigimod Brings Lasting Relief for Generalised Myasthenia Gravis Sufferers

Efgartigimod provides sustained improvement for patients with generalised myasthenia gravis, a recent analysis reveals. The therapy remains effective over time, benefiting those with acetylcholine-receptor autoantibodies. It offers hope, especially where traditional treatments fall short, establishing efgartigimod as a promising option in managing this condition.